Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study

Abstract

Ceftolozane-tazobactam is active against Gram-negative pathogens, including multidrug-resistant Pseudomonas aeruginosa In a subgroup analysis of patients with complicated intra-abdominal infections (cIAIs) involving P. aeruginosa from a phase 3 program, ceftolozane-tazobactam demonstrated potent in vitro activity against P. aeruginosa Clinical cure in the microbiologically evaluable population was 100% (26/26) for ceftolozane-tazobactam plus metronidazole and 93.1% (27/29) for meropenem. These findings support the use of ceftolozane-tazobactam in the management of cIAI when P. aeruginosa is suspected or confirmed. (This study has been registered at ClinicalTrials.gov under registration no. NCT01445665 and NCT01445678.).

Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Figures

FIG 1

MIC distribution and clinical outcomes with ceftolozane-tazobactam and meropenem. (A) Distribution of ceftolozane-tazobactam and meropenem MICs for 69 Pseudomonas aeruginosa isolates identified at the screening visit (microbiological intent-to-treat population). (B) Clinical cure rate at the test-of-cure visit for patients with and without baseline P. aeruginosa infection, by treatment group (microbiologically evaluable population, which includes patients with pathogens at baseline who were susceptible or resistant to study drug).